ICT-140 / EOM Pharma - LARVOL DELTA

A blended learning implementation package to increase HIV index case testing outcomes in Malawi: a cluster randomized controlled trial (AIDS 2024) - "Blended learning implementation package increased contact clients elicited, contact clients tested, and HIV self-test kits distribution compared to standard implementation and could be a useful tool for scaling up ICT programs."

Clinical • Late-breaking abstract • Human Immunodeficiency Virus • Infectious Disease

ImmunoCellular Therapeutics announces asset purchase agreement with private biotechnology company (PRNewswire) - "ImmunoCellular Therapeutics...announced an agreement with a privately held biotechnology company (the "Purchaser") for the purchase of substantially all of ImmunoCellular's remaining clinical and pre-clinical assets, including its preclinical and clinical programs, technology, intellectual property and know-how. ImmunoCellular's therapeutic assets are comprised of ICT-107 (phase 3-ready for glioblastoma), ICT-121 (phase 1 completed for recurrent glioblastoma) and ICT-140 (phase 1/2-ready for ovarian cancer), each of which is a patient-specific dendritic cell-based immunotherapy targeting solid tumors."

Licensing / partnership